journal article·2021-11-12Open access

Self-assembled micelles of the (lipo) glycopeptides, teicoplanin, as taxane nanocarriers

Laura Raquel Comini, Roxana Valeria Alasino, Victoria Leonhard, Karina Lilian Bierbrauer, Dante Miguel Beltramo

Nanotechnology· Volume 32· Issue 46

Abstract

Abstract The use of nanoparticles is one of the strategies currently studied to minimize the toxicity and lack of tissue specificity of many cancer drugs used in chemotherapy. In this research the physicochemical and biological behavior of a novel self-assembled nanostructure of the antibiotic Teicoplanin (Teico) was characterized as a nanocarrier system for solubilizing highly hydrophobic drugs like Paclitaxel (Ptx) in aqueous media. The Teico micelles were loaded with Ptx in DMSO or PEG-400. The interaction between the loaded micelles and Albumin human serum albumin (HSA) was then studied by size exclusion chromatography. Transmission electron microscopy, dynamic light scattering and high-resolution liquid chromatography were also used to characterize the physicochemical and structural properties of the micelles to form the Teico/Ptx and Teico/Ptx/HSA micelles. Cellular uptake of Ptx was evaluated by fluorescent microscopy. The in vitro cytotoxicity of the complexes was studied on Hep-2 tumor cells, by a Crystal Violet assay. Teico cosolvent-free micelles can solubilize up to 20 mg.ml −1 of Ptx dissolved in PEG, increasing four times the solubility of Ptx in water compared to Abraxane, and 20 000 times the intrinsic solubility of Ptx in water. In addition, Teico/Ptx micelles binds spontaneously HSA through hydrophobic interaction. Teico and Teico/HSA micelles as a Ptx transporter does not affect its release or biological activity. Therefore, Teico/Ptx or Teico/Ptx/HSA complexes appear as new alternatives for transporting larger amounts of hydrophobic drugs that offer advantages, turning it an interesting option for further study.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · Analytical Chemistry and Chromatography

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. Co-delivery of paclitaxel and doxorubicin by pH-responsive prodrug micelles for cancer therapy10.2147/IJN.S249144 ↗
2. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells10.1016/j.nano.2015.10.012 ↗
3. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review)10.3892/or.2017.5593 ↗
4. Improved antitumor efficacy of paclitaxel with nano-formulation in breast cancer10.1515/ntrev-2016-0059 ↗
5. A compressive review about taxol®: history and future challenges10.3390/molecules25245986 ↗
6. Paclitaxel and curcumin co-loaded mixed micelles: improving in vitro efficacy and reducing toxicity against Abraxane®10.1016/j.jddst.2021.102343 ↗
7. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cáncer10.1021/acsami.8b08125 ↗
8. A toxic organic solvent-free technology for the preparation of pegylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy10.2147/IJN.S92697 ↗
9. Improvement of the water-solubility of paclitaxel with an amorphous solid dispersing technique using polyvinylpyrrolidone as hydrophilic carrier
10. Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review)10.3892/mmr.2020.11580 ↗
11. Micellar drug delivery systems based on natural biopolymers10.3390/polym13030477 ↗
12. Development of paclitaxel-loaded poly(lactic acid)/hydroxyapatite core–shell nanoparticles as a stimuli-responsive drug delivery system10.1098/rsos.202030 ↗
13. Preparation and characterization of paclitaxel/chitosan nanosuspensions for drug delivery system and cytotoxicity evaluation in vitro10.1007/s42765-019-00012-z ↗
14. A novel paclitaxel microemulsion containing a reduced amount of cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety10.1155/2011/854872 ↗
15. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention10.1016/j.addr.2011.06.017 ↗
16. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation10.1016/S0959-8049(01)00171-X ↗
17. Self-assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes10.1016/j.jconrel.2012.07.031 ↗
18. chapter 24: Recent developments in using plant-derived natural products as tubulin inhibitors for the management of cancer10.1016/B978-0-12-802972-5.00024-X ↗
19. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms abraxane in multiple murine cancer models10.1038/ncomms8939 ↗
20. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
21. Albumin-bound paclitaxel: a next-generation taxane10.1517/14656566.7.8.1041 ↗
22. Clinical pharmacokinetics of teicoplanin10.2165/00003088-200039030-00001 ↗
23. Teicoplanina
24. Food · 2013
25. Crystal violet assay for determining viability of cultured cells10.1101/pdb.prot087379 ↗
26. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program10.1128/AAC.49.12.5024-5032.2005 ↗
27. Fluorescence assay to predict activity of the glycopeptide antibiotics10.1038/s41429-018-0120-5 ↗
28. Teicoplanin, antibiotics from Actinoplanes teichomyceticus Nov. Sp10.7164/antibiotics.37.988 ↗
29. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis10.1016/j.ijantimicag.2015.01.015 ↗
30. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy10.7150/thno.49577 ↗
31. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs10.1016/j.jconrel.2009.04.024 ↗
32. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature10.1016/j.nano.2011.05.003 ↗
33. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates10.1007/s11095-011-0460-3 ↗